Is Celldex Therapeutics Inc (CLDX) overvalued? · rev $7.0M
Celldex Therapeutics Inc (CLDX) is a biotechnology company listed on US.
This page asks whether Celldex Therapeutics Inc (CLDX) looks expensive on cached numbers — not a short thesis.
Latest reported CLDX revenue for 2024-12-31 was $7.0M. Revenue was up 2.0% from 2023-12-31 to 2024-12-31. CLDX currently screens at market cap $2.35B.
CLDX currently screens at market cap $2.35B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CLDX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CLDX stock page for the full model, not this heading.
Not investment advice.